A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones

NCT04521361 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Bone Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)

Sponsor

Bayer